

12-1-2020

Target treatment with stereotactic radiation for recurrent gliomas

Ayesha Ali

Victor E. Chen

Claire Zurlo

James M Taylor

Christian Fernandez

See next page for additional authors

Follow this and additional works at: <https://jdc.jefferson.edu/radoncfp>



Part of the [Oncology Commons](#), and the [Radiation Medicine Commons](#)

[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiation Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Ayesha Ali, Victor E. Chen, Claire Zurlo, James M Taylor, Christian Fernandez, and Wenyin Shi



Target treatment with stereotactic radiation for recurrent gliomas

Ayesha S. Ali¹, Victor E. Chen¹, Claire Zurlo², James M. Taylor¹, Christian Fernandez¹, Wenyin Shi¹

¹Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA; ²Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Contributions: (I) Conception and design: W Shi, AS Ali; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: AS Ali, C Zurlo, VE Chen; (V) Data analysis and interpretation: AS Ali, VE Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Wenyin Shi, MD, PhD. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Email: Wenyin.Shi@Jefferson.edu.

Abstract: High grade gliomas (HGG) have a propensity to recur locally and have poor outcomes. As such, safe and effective treatment is paramount. Target treatment with stereotactic radiation allows safe re-irradiation through minimizing normal brain tissue radiation due to its high precision. In this review, we evaluated the clinical experiences using SRS and FSRT for re-irradiation in HGG. We report the radiobiological advantages and disadvantages of both modalities as well as the safety and efficacy published in current literature.

Keywords: Stereotactic radiation; glioma; radiotherapy; re-irradiation

Submitted Feb 14, 2020. Accepted for publication Mar 04, 2020.

doi: 10.21037/cco.2020.03.05

View this article at: <http://dx.doi.org/10.21037/cco.2020.03.05>

Introduction

CNS malignancies account for an estimated 1.3% of new cancer cases annually and Glioblastoma Multiforme (GBM) is the most common (1). GBM accounts for 15.4% of all primary brain tumors and 45.6% of primary malignant brain tumors (2). Anaplastic Astrocytomas, another high grade glioma (HGG) accounts for 6.1% of all gliomas (3).

Standard of care for HGG entails maximal safe surgical resection followed by adjuvant radiotherapy (RT) and chemotherapy. Unfortunately, many patients recur within 5 to 8 months of definitive treatment (4). Historically, median survival after progression is 6 months (5). While the use of radiotherapy in the primary setting for HGG has been well established, the treatment paradigm in the recurrent setting is less elucidated and varies by institution (4-13). Salvage therapies used alone or in combination include surgery, re-irradiation, systemic treatment, tumor treatment fields (TTF) or palliation. Studies have shown a survival benefit with salvage treatment versus palliation (13). Currently, there remains a paucity of data and a lack of general consensus regarding the optimal management strategy for recurrent HGG.

Since the advent of stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), more precise and focused targeting is now available and may be preferable in the re-irradiation/salvage setting (14). Various doses and fractionation schedules have been utilized, largely guided by location and volume of recurrence, with various levels of success. In general, SRS has been used for low volume disease while FSRT has been reserved for large volume recurrence (e.g., >4 cm), and allows safe delivery by taking advantage of the radiobiological benefits of fractionation (15,16). Given the poor prognosis of this patient group, efficacy must be balanced by the potential impact on patient quality of life. Herein, we review the various salvage RT series and their respective outcomes.

Radiobiology and physics of SRS and FSRT

There are key physics, radiobiologic, and dosimetric concepts to recall when evaluating SRS and FSRT regimens for recurrent HGG. From a physics perspective, the basic principles underlying conventionally delivered radiation therapy also guide the clinical use of SRS and

FSRT. However, SRS and FSRT require a much higher level of accuracy given the modality delivers very high radiation doses over a single or few fractions. Millimeter-level precision is required in patient positioning with high reproducibility, which can be achieved either with a frame, or as is more common today, with a frameless, mask-based system (17). Target definition accuracy as well as precise image guidance is also critical with the small margins used in SRS and FSRT treatments. Radiobiologically, the literature suggests that high-dose, single fraction treatment primarily acts on tumor-supporting endothelial cells for its tumoricidal effects; in other words, the radiation response can be seen not only in the tumor cells themselves but also in the vasculature (18). The small margins required for SRS and FSRT limit collateral damage to normal tissues.

Kirkpatrick *et al.* noted that the immunostimulatory effects of SRS and FSRT are important to consider, especially with the growing role of immunotherapy in cancer treatment (19). They argue that although vascular damage may limit the ability of antigens to stimulate the immune system, a hypofractionated regimen such as FSRT, may leave antigen transport mostly intact and result in a stronger immune response than SRS. This is an emerging field of study which has the potential to shift the landscape of radiation techniques in the coming years.

SRS

In a recent systematic review of SRS in HGG the authors report a median overall survival (OS) of 20 months and progression free survival (PFS) of 5.42 months. In this study, the pooled rate of radiation necrosis (RN) was 5.9% but ranged from 0–44% (20). Another review deems SRS a safe and effective minimally invasive treatment for recurrent HGG. They report OS of 13–26 months after recurrence (21).

Dose

Several prospective trials and retrospective studies have explored dose and fractionation schedules for SRS in recurrent gliomas (Table 1). Doses ranged from 9 to 25 Gy. In some cases, up to 9 lesions were treated with SRS. Others limited SRS to small lesions which were defined differently depending on the study. Generally, doses were attenuated based on size and location of the lesion. Larger lesions and those in proximity to critical structures were prescribed lower doses.

Koga *et al.* published a study detailing the local control benefits of extended-field SRS. They evaluated the impact of adding a margin of 0.5- to 1.0-cm around the enhancing tumor. This study reported a statistically significant difference in local control between extended-field and conventional SRS. However, OS was not statistically significant between conventional and extended-field SRS groups and rates of RN were slightly higher in the population (n=9, 35 lesions) studied (26).

Historically, median survival from progression for GBM has been reported as 6 months whether the patients were treated with RT and TMZ upfront or not (5). Studies included in this review had a median OS from SRS ranging from 7 to 14.4 months with a median of 10.6. However, about half (10) studies included both WHO grade III and grade IV gliomas which may favorably skew the OS.

Safety

The majority of HGG will recur within 2 cm of the initial (pre-surgical) tumor bed which makes previous RT pertinent to the safety of re-irradiation (27,28). Normal tissue radiation tolerance is dependent on the volume treated, dose, and sensitivity of tissue being treated. Due to the highly conformal nature of both SRS and FSRT, treatment margins are eliminated and less healthy brain tissue is included in the field. This is especially relevant in the recurrent setting in which the majority of patients have already received RT to the area in question (15).

RTOG 9005 explored maximum tolerated dose of SRS in patients with a history of prior RT in primary brain tumors. Although the trial did not focus on gliomas with previous RT up to 60 Gy, it showed that maximum tolerated doses varied based on tumor diameter and that tumor diameter correlated with risk of grade ≥ 3 neurotoxicity. Twenty-four Gy, 18 Gy and 15 Gy were defined as the maximum tolerated doses for tumors ≤ 2 , 2–3 and 3–4 cm respectively (29). Several phase I dose escalation trials have shown varying risk of radionecrosis when utilizing doses above those in RTOG 9005 (30–32).

RN is perhaps the most serious late side effect of CNS RT. It occurs in brain tissue that has received a normalized tissue dose (NTD) of >100 Gy. Changes in RT technique at re-treatment have not been correlated with an increased risk of this phenomenon. Low initial dose and long intervals between treatments may lead to less neurotoxicity (33–35). Clinically, RN can imitate tumor recurrence with worsening presenting symptoms, new neurological deficits as well as

Table 1 SRS in recurrent HGG

First author	Year	Patients	Grade	Dose	Systemic therapy	MS from diagnosis	MS from SRS	Grade ≥3 toxicity
Cho	1999	46	Grade III/IV	17 Gy	-	-	11	18% RN with salvage craniotomy
Combs	2005	32	Grade IV	10–20 Gy (median 15)	None	22	10	None
Kong	2008	114	Grade III/IV	12–50 Gy (median 16)	-	37.5		24.4% RN
Patel	2009	26	Grade IV	12–20 Gy (median 18)	All patients received either irinotecan, erlotinib, bevacizumab, carmustine, lomustine or TMZ	24.4	8.5	8% RN with salvage craniotomy
Cuneo	2009	63	Grade III/IV	12.5–25 Gy (median 15)	Bevacizumab, Irinotecan, Lomustine	41	10	13%
Cabrera	2013	15	Grade III/IV	18–24 or 25 in 5 fractions based on size	Bevacizumab	-	14.4	7%
Pinzi	2015	128	Grade III/IV	6–22 (median 15)	25% received systemic therapy	32	11.5	6%
Bokstein	2016	47	Grade III/IV	14–24 (median 18)	40% received systemic therapy (TMZ, bevacizumab, carboplatin)	37.4	15.9	5.5% RN
Niranjan (22)	2015	297	Grade IV	9–25 (median 15)		18.1	9.03	23%
Frischer	2016	42	Grade IV	Median 20	83% received chemotherapy	25.6	9.6	2% RN
Imber	2017	174	Grade IV	10–22 Gy (median 16)	44% received systemic therapy	19.1	10.6	26% RN with salvage craniotomy
Sutera	2017	55	Grade IV (LGG also included in study)	9–30 (median 21)		23.9	10.25	1.50%
Sharma	2019	53	Grade IV	12–24 Gy (median 18)	77% received systemic therapy		11	4% RN
Elliott	2011	26	Grade III/IV	10–18 Gy (median 15)	19.2% received systemic therapy	25.5	13.5	15%
Maranzano	2018	13	Grade IV	14–22 Gy (median 17)	14% received systemic therapy		11	23% RN
Conti (23)	2012	23	Grade IV	Median 20 Gy	52% received “dose dense” TMZ		12 (TMZ), 7 (no TMZ)	22%
Skeie (24)	2012	61	Grade IV	8–20 Gy (median 12.2)		17	12	9.8% RN
Koga	2011	9	Grade IV	20 Gy		24	10.5	22% RN
Martínez-Carrillo (25)	2014	87	Grade III/IV	14–20 Gy (Median 18)		21	10	10% RN

MS, median survival; SRS, stereotactic radiosurgery; RN, radiation necrosis; TMZ, temozolomide; LGG, low grade glioma.

progressing enhancement on imaging. It may ultimately require surgical debulking. Other less invasive treatments may include bevacizumab, corticosteroids or hyperbaric oxygen (15,36).

Some studies showed no grade 3 or higher toxicities while others demonstrated that up to 26% of patients suffered clinically significant toxicities. A phase I dose escalation trial showed clinically significant toxicities of up to 60% however there were only 10 patients enlisted in the trial. Only one experienced neurotoxicity and other toxicities were associated with the concurrent systemic therapy (32). In one institutional report, 26% of 174 GBM patients underwent salvage craniotomy for RN. This report found that larger mean treatment volumes may have predicted for RN. Median volume of lesions treated with SRS in this retrospective study was 7 cc with a maximum of 39 cc (37). Another report found that 23% of patients experienced RN, however, this only represented 3 patients all three of which had different treatment volumes and different doses (38). Kong *et al.* reported a 24.4% RN rate but further analysis was not commented on. All of these studies used a median of 16 or 17 Gy (39).

Only one patient in a study by Suter *et al.* experienced RN (grade 2), but not all patients were strictly treated with SRS. They included up to 8 fractions in their retrospective analysis (40). Another report found only one patient to have RN out of their 42-patient cohort. Additional disease-specific data was not offered regarding this patient, but the median dose in this study was 20 Gy (41).

Cabrera *et al.* included neurocognitive testing and quality of life parameters in their prospective trial of concurrent SRS and bevacizumab. This was assessed through the Mini-Mental State Examination (MMSE), Trail Making Test Parts A and B (TMT-A/B) and Functional Assessment of Cancer Therapy-Brain (FACT-Br) at baseline, 1 week and 2 months after SRS. Although they reported that neurocognition didn't change during treatment, the physical well-being subscale of the FACT-Br showed significant worsening at the two-month time point compared to baseline or one week evaluations (42).

Systemic therapy

Varying combinations of systemic therapy and steroids were used in these studies. Doses of these agents also varied. Some patients were pretreated with steroids and others weren't treated with steroids until clinical symptoms worsened. Not all concurrent or adjuvant treatments were

detailed in published reports of the included studies.

Bokstein *et al.* reported a significant survival advantage in GBM patients treated with SRS *vs.* bevacizumab alone (12.6 *vs.* 7.3 months) (43). However, tumor burden and volume was not matched in this retrospective study and 40% of the patients in the SRS group received concurrent chemotherapy or biological therapy. Suter *et al.* described an association between bevacizumab and inferior outcomes, however, only two patients received bevacizumab in their analysis (40). In contrast, Cuneo *et al.* described a survival benefit in patients receiving adjuvant bevacizumab after salvage SRS (11.2 *vs.* 3.9 months). They also reported a PFS benefit in this population (5.2 *vs.* 2.1 months) without any additional toxicity (36). Most patients included in this retrospective analysis received multiple courses of salvage systemic therapies including irinotecan, lomustine, etoposide and bevacizumab prior to SRS. Another prospective trial found that a small cohort of patients tolerated concurrent bevacizumab with SRS (42). The impact of other systemic therapies is difficult to deduce as many included studies were retrospective in nature and the included patient population received multiple agents (36, 43-46).

Prognostic indicators

Cho *et al.* compared SRS and FSRT in recurrent HGG retrospectively and found that the two treatments yielded comparable survival. Although this was a non-randomized study, favorable prognostic factors included smaller tumor volume, younger age, high KPS and lower grade (47). Several other studies found age and performance status to be significantly associated with survival (40,41,45). Two other retrospective reports showed that higher KPS and small tumor volume predicted for increased OS (48).

Time to recurrence may also play a role in predicting OS benefit. One retrospective study reported that longer interval between initial aggressive resection and recurrence correlated with survival (48). Similarly, Maranzano *et al.* described a potential survival benefit in patients that had adequate time (≥ 5 months) between initial RT and RT at recurrence (38).

Patel *et al.* published a retrospective study stating survival was significantly improved in patients who either responded or had stable disease after SRS with median survival of 15.8 *vs.* 7.3 following radiosurgery (44). Interestingly, it has also been reported that patients treated after 2005 survive longer than those treated prior to this year. Sharma

Table 2 FSRT in recurrent HGG

First author	Year	Number of patients	WHO grade	Dose and fractionation	Systemic therapy	MS from diagnosis (months)	MS from FSRT (months)	Grade ≥ 3 toxicity
Hudes	1997	20	Grade III/IV	24–35 Gy, 8–10 fx	None	–	10.5	0%
Cho (47)	1999	25	Grade III/IV	20–45 Gy, 10–20 fx, median: 37.5 Gy	None	–	12	30%
Combs (49)	2005	40	Grade III	20–57.6 Gy, 2 Gy/fx, median: 36 Gy	None	48	16	0%
Combs	2005	172	Grade II-IV	15–62 Gy, 2 Gy/fx, median: 36 Gy	None	21/50/111; Gr IV/III/II	8/16/22; Gr IV/III/II	0%
Combs (50)	2008	25	Grade II-IV	25–45 Gy, 2 Gy/fx, median: 36 Gy	TMZ	59	8	0%
Schwer	2008	15	Grade III/IV	36 Gy, 3 fx	Gefitinib	29	10	13%
Gutin (51)	2009	25	Grade III/IV	30 Gy, 5 fx	Bevacizumab	–	12.5	28%
Patel	2009	10	Grade IV	36 Gy, 6 fx	Multiple	24.1	7.4	10%
Minniti	2010	36	Grade IV	37.5 Gy, 15 fx	TMZ	23.4	9.7	8%
Fields	2012	10	Grade III/IV	36 Gy, 3 fx	Vandetanib	26.5	6	30%
Clark (52)	2014	21	Grade III/IV	30 Gy, 5 fx	TMZ, CCNU, Bevacizumab	–	12.5	5%
Greenspoon (53)	2014	31	Grade IV	25–35 Gy, 5 fx	TMZ	–	9	13%
Wuthrick (54)	2014	11	Grade III/IV	30–42 Gy, 10 fx	Sunitinib	–	11	9%
Shi	2016	12	Grade III/IV	30–35 Gy, 10 fx	Panobinostat	–	6.1–16.1	58%
Shi	2018	36	Grade II-IV	30–37.5 Gy, 10 fx	Bevacizumab	24.9	4.8	0%
Song (55)	2019	17	Grade III/IV	30–35 Gy, 10 fx	Alisertib	–	11.1	24%

FSRT, fractionated stereotactic radiotherapy; HGG, high grade glioma; WHO, World Health Organization; MS, median survival; TMZ, temozolomide; Gy, Gray; fx, fraction.

et al. hypothesizes that this could be due to the treatment standardization of GBM patients after the publication of the Stupp protocol or that their institution started prescribing higher median prescription doses to smaller volumes around that time (46).

MGMT promoter methylation status is known to be a favorable prognostic factor in GBM patients. However, only a handful of the included studies documented MGMT status. One study showed a significant median OS benefit in patients with MGMT promoter methylation (33.4 *vs.* 16 months). However, only 22 patients had MGMT sequencing at the time of this study (41). Another report had 11 patients with MGMT promoter methylation, but did not find a statistically significant difference between OS in the cohort (40). A third study included 15 patients with MGMT sequencing results and only 5 with MGMT

promoter methylation. Survival statistics were not provided on this subgroup (46).

Imber *et al.* reported a trend toward decreased OS in patients in which multiple targets were treated with SRS (37,38). Twenty-one percent of patients in one study had multiple lesions upon recurrence. It is unclear how many of those recurrent lesions were treated with SRS, but their survival was similar to the other studies included in this review. Pinzi *et al.* did not find any significant OS difference between patients with multiple treated lesions *vs.* a single lesion (45).

FSRT

There have been a variety of dose and fractionation regimens used for FSRT treatment in the setting of

recurrent high-grade glioma, as detailed in *Table 2*. In a study comparing the efficacy of SRS versus FSRT in recurrent WHO Grade III and Grade IV tumors, Cho *et al.* used a median dose of 37.5 Gy in 15 fractions for their FSRT arm (47). Similarly, Minniti *et al.* evaluated the efficacy of salvage FSRT in combination with TMZ with a dose of 37.5 Gy in 15 fractions (56). Both of these studies represent modestly hypofractionated radiation regimens with 2.5 Gy per fraction. In contrast, a Phase I dose-escalation study investigating FSRT given in combination with gefitinib for recurrent HGG, Schwer *et al.* were able to deliver 36 Gy in 3 fractions without dose-limiting toxicity (31). In addition, Fields *et al.* gave 36 Gy in 3 fractions of FSRT in combination with dose-escalated vandetanib in their phase I trial for recurrent malignant glioma. These two trials represent the most aggressively hypofractionated FSRT regimens, with biologically effective dose approaching that of SRS regimens (32). The median dose of the literature surveyed in this review as shown in *Table 2* is approximately 35 Gy in 10 fractions, although many trials did allow for dose variation to account for prior radiation dose, proximity to critical structures, and size of the recurrent lesion.

Toxicity remains a concern with FSRT treatment for recurrent high-grade glioma, although perhaps to a lesser degree as compared to SRS, given the normal tissue repair capacity between fractions of radiation. Many of the FSRT studies referenced in *Table 2* quoted a zero percent rate of Grade III or higher toxicity. Hudes *et al.*'s paper aimed to determine the optimal dose of FSRT while decreasing rates of re-operation due to SRS toxicity (30). Shi *et al.*'s 2018 retrospective review of recurrent HGG patients who progressed on bevacizumab and subsequently received FSRT also noted no treatment-related Grade III or higher toxicity (57). In contrast, a Phase I study investigating the role of combining panobinostat and FSRT reported a 58% rate of Grade III or higher toxicity, although much of this was hematologic and associated with the oral radiosensitizing agent, with only one Grade III RN event (58). In direct comparison studies, such as Cho *et al.*, of FSRT versus SRS—where the confounder of concurrent systemic therapy was not present—toxicity rates as a whole, and particularly radiation necrosis rates, are significantly lower when using FSRT (47).

Conclusion

Both SRS and FSRT have shown efficacy and safety in

a variety of different dose and fractionation schedules in recurrent HGG. Further conclusions are difficult to delineate as the included studies used varying inclusion criteria, doses, and systemic therapies (concurrent or adjuvant). It is important to note that the majority of the included studies did not comment on MGMT status which is known to impact survival. Most studies included in this review reported toxicity of therapeutic intervention, but few recorded quality of life and neurocognitive changes. Further prospective trials are ongoing and necessary to further elucidate a standard of care for these patients.

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/cco.2020.03.05>). WS: Consulting for Novocure, Brainlab, and Varian. Research funding from Regeneron, Brainlab, Novocure. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.
2. Diwanji TP, Engelman A, Snider JW, et al. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. *Adolesc Health Med Ther* 2017;8:99.

3. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. *Neuro Oncol* 2015;17:iv1-62.
4. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987-96.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 2009;10:459-66.
6. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol* 2013;31:337.
7. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. *Eur J Cancer* 2012;48:2192-202.
8. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg* 2001;95:190-8.
9. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med* 2014;370:699-708.
10. van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. *Lancet* 2017;390:1645-53.
11. Laub CK, Stefanik J, Doherty L. Approved treatments for patients with recurrent high-grade gliomas. *Semin Oncol Nurs* 2018;34:486-93.
12. Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma are we there yet?. *Neuro Oncol* 2013;15:4-27.
13. Shi W, Bryan MS, Gilbert MR, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology/radiation therapy oncology group trial 0525. *Int J Radiat Oncol Biol Phys* 2018;100:38-44.
14. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. *J Clin Oncol* 2010;28:3048.
15. Halperin EC, Brady LW, Pérez CA. Perez and Bradys principles and practice of radiation oncology. Philadelphia: Wolters Kluwer; 2019.
16. Combs SE, Debus J, Schulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. *Bmc Cancer* 2007;7:167.
17. Chin LS, Regine WF. Principles and practice of stereotactic radiosurgery. Springer Science & Business Media; 2010.
18. Brady LW, Perez CA, Wazer DE. Perez & Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins; 2013.
19. Kirkpatrick JP, Soltys SG, Lo SS, et al. The radiosurgery fractionation quandary: single fraction or hypofractionation?. *Neuro Oncol* 2017;19:ii38-49.
20. Fetcko K, Lukas RV, Watson GA, et al. Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas. *Medicine (Baltimore)* 2017;96:e8293.
21. Elaimy AL, Mackay AR, Lamoreaux WT, et al. Clinical outcomes of gamma knife radiosurgery in the salvage treatment of patients with recurrent high-grade glioma. *World Neurosurg* 2013;80:872-8.
22. Niranjana A, Kano H, Iyer A, et al. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. *J Neurosurg* 2015;122:757-65.
23. Conti A, Pontoriero A, Arpa D, et al. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. *Acta Neurochirurgica* 2012;154:203-9.
24. Skeie BS, Enger PØ, Brøgger J, et al. Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme. *World Neurosurg* 2012;78:658-69.
25. Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, et al. Salvage radiosurgery for selected patients with recurrent malignant gliomas. *Biomed Res Int* 2014;2014:657953.
26. Koga T, Maruyama K, Tanaka M, et al. Extended field stereotactic radiosurgery for recurrent glioblastoma. *Cancer* 2012;118:4193-200.
27. Ene CI, Macomber MW, Barber JK, et al. Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. *Neurosurgery* 2019;85:E322-31.
28. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. *Int J Radiat Oncol Biol Phys*

- 1989;16:1405-9.
29. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. *Int J Radiat Oncol Biol Phys* 2000;47:291-8.
 30. Hudes RS, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. *Int J Radiat Oncol Biol Phys* 1999;43:293-8.
 31. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys* 2008;70:993-1001.
 32. Fields EC, Damek D, Gaspar LE, et al. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys* 2012;82:51-7.
 33. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys* 1991;21:109-22.
 34. Mayer R, Sminia P. Reirradiation tolerance of the human brain. *Int J Radiat Oncol Biol Phys* 2008;70:1350-60.
 35. Sminia P, Mayer R. External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. *Cancers* 2012;4:379-99.
 36. Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys* 2012;82:2018-24.
 37. Imber BS, Kanungo I, Braunstein S, et al. Indications and efficacy of gamma knife stereotactic radiosurgery for recurrent glioblastoma: 2 decades of institutional experience. *Neurosurgery* 2017;80:129-39.
 38. Maranzano E, Anselmo P, Casale M, et al. Treatment of recurrent glioblastoma with stereotactic radiotherapy: long-term results of a mono-institutional trial. *Tumori* 2011;97:56-61.
 39. Kong DS, Lee JI, Park K, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. *Cancer* 2008;112:2046-51.
 40. Suter PA, Bernard ME, Gill BS, et al. Salvage stereotactic radiosurgery for recurrent gliomas with prior radiation therapy. *Future Oncol* 2017;13:2681-90.
 41. Frischer JM, Marosi C, Woehrer A, et al. Gamma knife radiosurgery in recurrent glioblastoma. *Stereotact Funct Neurosurg* 2016;94:265-72.
 42. Cabrera AR, Cuneo KC, Desjardins A, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. *Int J Radiat Oncol Biol Phys* 2013;86:873-9.
 43. Bokstein F, Blumenthal DT, Corn BW, et al. Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. *J Neurooncol* 2016;126:551-7.
 44. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. *J Neurooncol* 2009;92:185.
 45. Pinzi V, Orsi C, Marchetti M, et al. Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. *Neurol Sci* 2015;36:1431-40.
 46. Sharma M, Schroeder JL, Elson P, et al. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. *J Neurosurg* 2018;131:489-99.
 47. Cho KH, Hall WA, Gerbi BJ, et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. *Int J Radiat Oncol Biol Phys* 1999;45:1133-41.
 48. Elliott RE, Parker EC, Rush SC et al. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. *World Neurosurg* 2011;76:128-40.
 49. Combs SE, Gutwein S, Thilmann C, et al. Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). *Strahlenther Onkol* 2005;181:768-73.
 50. Combs SE, Bischof M, Welzel T, et al. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. *J Neurooncol* 2008;89:205-10.
 51. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys* 2009;75:156-63.
 52. Clark GM, McDonald AM, Nabors L, et al. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. *Neurooncol Pract* 2014;1:172-7.
 53. Greenspoon JN, Shariieff W, Hirte H, et al. Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma

- multiforme: a prospective cohort study. *Onco Targets Ther* 2014;7:485.
54. Wuthrick EJ, Curran Jr WJ, Camphausen K, et al. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. *Int J Radiat Oncol Biol Phys* 2014;90:369-75.
55. Song A, Andrews DW, Werner-Wasik M, et al. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. *Radiother Oncol* 2019;132:135-41.
56. Minniti G, Armosini V, Salvati M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. *J Neurooncol* 2011;103:683-91.
57. Shi W, Blomain ES, Siglin J, et al. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. *J Neurooncol* 2018;137:171-7.
58. Shi W, Palmer JD, Werner-Wasik M, et al. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. *J Neurooncol* 2016;127:535-9.

Cite this article as: Ali AS, Chen VE, Zurlo C, Taylor JM, Fernandez C, Shi W. Target treatment with stereotactic radiation for recurrent gliomas. *Chin Clin Oncol* 2020;9(6):74. doi: 10.21037/cco.2020.03.05